VOYA INVESTMENT MANAGEMENT LLC - SANGAMO THERAPEUTICS INC ownership

SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 134 filers reported holding SANGAMO THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.23 and the average weighting 0.0%.

Quarter-by-quarter ownership
VOYA INVESTMENT MANAGEMENT LLC ownership history of SANGAMO THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$34,890
-53.9%
58,1700.0%0.00%
Q2 2023$75,621
-13.2%
58,170
+17.5%
0.00%
Q1 2023$87,152
-43.9%
49,5180.0%0.00%
Q4 2022$155,487
-35.9%
49,5180.0%0.00%
Q3 2022$242,638
+25.7%
49,518
+6.4%
0.00%
Q2 2022$193,000
-28.8%
46,5580.0%0.00%
-100.0%
Q1 2022$271,000
-22.3%
46,5580.0%0.00%0.0%
Q4 2021$349,000
-18.6%
46,558
-2.2%
0.00%0.0%
Q3 2021$429,000
-24.7%
47,6240.0%0.00%0.0%
Q2 2021$570,000
-9.8%
47,624
-5.6%
0.00%0.0%
Q1 2021$632,000
-19.5%
50,434
+0.3%
0.00%
-50.0%
Q4 2020$785,000
+106.6%
50,291
+25.1%
0.00%
+100.0%
Q3 2020$380,000
+5.6%
40,2130.0%0.00%0.0%
Q2 2020$360,000
-1.9%
40,213
-30.2%
0.00%0.0%
Q1 2020$367,000
-21.2%
57,577
+3.3%
0.00%0.0%
Q4 2019$466,000
+16.8%
55,723
+26.4%
0.00%0.0%
Q3 2019$399,000
-16.0%
44,0980.0%0.00%0.0%
Q2 2019$475,000
+18.8%
44,098
+5.1%
0.00%0.0%
Q1 2019$400,000
-17.0%
41,9590.0%0.00%0.0%
Q4 2018$482,000
-28.6%
41,959
+5.4%
0.00%0.0%
Q3 2018$675,000
+19.5%
39,8070.0%0.00%0.0%
Q2 2018$565,000
-19.7%
39,807
+7.5%
0.00%
-50.0%
Q1 2018$704,000
+12.8%
37,034
-2.6%
0.00%
+100.0%
Q4 2017$624,000
+9.5%
38,0270.0%0.00%0.0%
Q3 2017$570,000
+91.3%
38,027
+12.5%
0.00%0.0%
Q2 2017$298,000
+87.4%
33,809
+10.7%
0.00%
Q1 2017$159,000
+71.0%
30,5390.0%0.00%
Q4 2016$93,000
-98.5%
30,539
-97.7%
0.00%
-100.0%
Q3 2016$6,275,000
-8.3%
1,355,208
+14.7%
0.01%
-29.4%
Q2 2016$6,843,000
+0.7%
1,181,883
+5.2%
0.02%0.0%
Q1 2016$6,797,000
-32.9%
1,123,458
+1.3%
0.02%
-32.0%
Q4 2015$10,126,000
+35.6%
1,109,012
-16.2%
0.02%
+31.6%
Q3 2015$7,466,000
-30.7%
1,323,662
+36.4%
0.02%
-24.0%
Q2 2015$10,766,000
-6.4%
970,753
+32.4%
0.02%
-3.8%
Q1 2015$11,496,000
+27.7%
733,174
+23.9%
0.03%
+30.0%
Q4 2014$9,003,000
+1704.2%
591,913
+1178.1%
0.02%
+1900.0%
Q3 2014$499,000
-29.4%
46,3130.0%0.00%
-50.0%
Q2 2014$707,000
-15.5%
46,3130.0%0.00%0.0%
Q1 2014$837,000
+30.2%
46,3130.0%0.00%
+100.0%
Q4 2013$643,000
+32.6%
46,3130.0%0.00%0.0%
Q3 2013$485,000
+34.0%
46,3130.0%0.00%0.0%
Q2 2013$362,00046,3130.00%
Other shareholders
SANGAMO THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Golden State Equity Partners 154,360$897,0000.45%
Rhenman & Partners Asset Management AB 761,429$4,424,0000.44%
Lombard Odier Asset Management (Switzerland) SA 860,702$5,001,0000.39%
WASATCH ADVISORS LP 10,576,997$61,452,0000.30%
Rokos Capital Management LLP 977,663$5,861,0000.27%
KLK CAPITAL MANAGEMENT LLC 44,323$258,0000.26%
Long Focus Capital Management, LLC 340,000$1,975,0000.25%
Vanguard Capital Wealth Advisors 33,380$193,0000.14%
Fort Sheridan Advisors LLC 73,978$430,0000.13%
Delphia (USA) Inc. 20,983$122,0000.09%
View complete list of SANGAMO THERAPEUTICS INC shareholders